Type your tag names separated by a space and hit enter

Amiodarone for maintaining sinus rhythm after cardioversion of atrial fibrillation

Evidence Summaries

Level of Evidence = A

Amiodarone is more effective than placebo in reducing atrial fibrillation recurrence.

A Cochrane review 1 on antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation included 59 studies with a total of 21,305 subjects. Amiodarone was included in 13 of the studies (n=2,630), and 6 of them compared amiodarone with placebo or no treatment. Compared to placebo/no treatment amiodarone reduced atrial fibrillation recurrence (Peto OR 0.19, 95% CI 0.14 to 0.26; 6 studies, n=812). In direct comparisons between antiarrhythmics, amiodarone reduced recurrences of atrial fibrillation significantly more than combined class I drugs (Peto OR 0.36, 95% CI 0.26 to 0.50; 5 studies, n=643), more than dronedarone (Peto OR 0.45, 95% CI 0.31 to 0.63; 1 study; n=504), and more than sotalol (Peto OR 0.42, 95% CI 0.33 to 0.53; 6 studies, n=1,168). When compared with placebo or other antiarrhytmics, amiodarone showed no significant difference in mortality. Pooled recurrence rates of atrial fibrillation at 1 year were high: 69% to 84% in controls not receiving antiarrhythmic treatment, reduced to 43% to 67% in patients treated with antiarrhythmics. The corresponding average NNT for 1 year, to avoid 1 recurrence of atrial fibrillation, were 3 with amiodarone, 4 with flecainide, 5 with dofetilide and propafenone, 8 with quinidine and sotalol and 10 with dronedarone and metoprolol and 17 with azimilide (the 95% CI varied between 2 and 60).

Amiodarone produced significantly fewer withdrawals (Peto OR 0.55, 95% CI 0.36 to 0.84; 5 studies, n=652) and less proarrhythmic events (Peto OR 0.28, 95% CI 0.13 to 0.59; 3 studies, n=475) than class I drugs combined. However, compared to placebo, amiodarone had a high OR for increasing withdrawals (Peto OR 5.64, 95% CI 2.34 to 13.63; 4 studies, n=319).

References

1. Lafuente-Lafuente C, Valembois L, Bergmann JF et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2015;(3):CD005049.  [PMID:25820938]


Copyright © 2017 Duodecim Medical Publications Limited.
Amiodarone for maintaining sinus rhythm after cardioversion of atrial fibrillation is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.

Citation

"Amiodarone for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/457026/all/Amiodarone_for_maintaining_sinus_rhythm_after_cardioversion_of_atrial_fibrillation.
Amiodarone for maintaining sinus rhythm after cardioversion of atrial fibrillation. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/457026/all/Amiodarone_for_maintaining_sinus_rhythm_after_cardioversion_of_atrial_fibrillation. Accessed March 24, 2019.
Amiodarone for maintaining sinus rhythm after cardioversion of atrial fibrillation. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/457026/all/Amiodarone_for_maintaining_sinus_rhythm_after_cardioversion_of_atrial_fibrillation
Amiodarone for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 March 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/457026/all/Amiodarone_for_maintaining_sinus_rhythm_after_cardioversion_of_atrial_fibrillation.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Amiodarone for maintaining sinus rhythm after cardioversion of atrial fibrillation ID - 457026 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/457026/all/Amiodarone_for_maintaining_sinus_rhythm_after_cardioversion_of_atrial_fibrillation PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -